ImmunityBio Inc (NASDAQ:IBRX) has a beta value of 0.96 and has seen 1.26 million shares traded in the recent trading session. The company, currently valued at $3.12B, closed the recent trade at $4.51 per share which meant it lost -$0.03 on the day or -0.69% during that session. The IBRX stock price is -133.48% off its 52-week high price of $10.53 and 72.28% above the 52-week low of $1.25. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.23 million shares traded. The 3-month trading volume is 3.43 million shares.
The consensus among analysts is that ImmunityBio Inc (IBRX) is Sell stock at the moment, with a recommendation rating of 2.00. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 0 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is 0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ImmunityBio Inc (NASDAQ:IBRX) trade information
Sporting -0.69% in the red today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the IBRX stock price touched $4.51 or saw a rise of 5.45%. Year-to-date, ImmunityBio Inc shares have moved -10.18%, while the 5-day performance has seen it change 2.47%. Over the past 30 days, the shares of ImmunityBio Inc (NASDAQ:IBRX) have changed -31.89%. Short interest in the company has seen 48.48 million shares shorted with days to cover at 14.53.
Wall Street analysts have a consensus price target for the stock at $8, which means that the shares’ value could jump 43.62% from the levels at last check today. The projected low price target is $8.0 while the price target rests at a high of $8.0. In that case, then, we find that the latest price level in today’s session is -77.38% off the targeted high while a plunge would see the stock gain -77.38% from the levels at last check today.
ImmunityBio Inc (IBRX) estimates and forecasts
Figures show that ImmunityBio Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -1.55% over the past 6 months, with this year growth rate of 24.24%, compared to 16.80% for the industry. Revenue growth from the last financial year stood is estimated to be 11,403.20%.
1 analysts offering their estimates for the company have set an average revenue estimate of 2.52M for the current quarter. 1 have an estimated revenue figure of 10.03M for the next ending quarter. Year-ago sales stood 41k and 82k respectively for this quarter and the next, and analysts expect sales will grow by 6,046.30% for the current quarter and 11,403.20% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 1.17% over the past 5 years. Earnings growth for 2024 is a modest 35.22% while over the next 5 years, the company’s earnings are expected to decrease by -1.70%.
IBRX Dividends
ImmunityBio Inc is expected to release its next earnings report 2024-Aug-12 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ImmunityBio Inc (NASDAQ:IBRX)’s Major holders
Insiders own 77.59% of the company shares, while shares held by institutions stand at 10.11% with a share float percentage of 45.13%. Investors are also buoyed by the number of investors in a company, with ImmunityBio Inc having a total of 239.0 institutions that hold shares in the company. The top two institutional holders are STATE STREET CORP with over 14.18 million shares worth more than $76.17 million. As of 2024-03-31, STATE STREET CORP held 2.7887% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 13.54 million shares as of 2024-03-31. The firm’s total holdings are worth over $72.71 million and represent 2.6619% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. As of Jun 30, 2024, the former fund manager holds about 0.63% shares in the company for having 4.38 shares of worth $19.82 million while later fund manager owns 4.2 shares of worth $19.02 million as of Mar 31, 2024, which makes it owner of about 0.61% of company’s outstanding stock.
